Cargando…
Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models
Autores principales: | Spahn, Jessica, Peng, Jing, Lorenzana, Edward, Kan, David, Hunsaker, Thomas, Segal, Ehud, Mautino, Mario, Brincks, Erik, Pirzkall, Andrea, Kelley, Sean, Mahrus, Sami, Liu, Liling, Dale, Stephanie, Quiason, Cristine, Jones, Elizabeth, Liu, Yichin, Latham, Sheerin, Salphati, Laurent, DeMent, Kevin, Merchant, Mark, Hatzivassiliou, Georgia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649373/ http://dx.doi.org/10.1186/2051-1426-3-S2-P303 |
Ejemplares similares
-
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
por: Nayak-Kapoor, Asha, et al.
Publicado: (2018) -
Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours
por: Ebata, Takahiro, et al.
Publicado: (2019) -
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
por: Tunger, Antje, et al.
Publicado: (2019) -
The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015) -
Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
por: Puccini, Alberto, et al.
Publicado: (2020)